title: Pharmacokinetics of diacerein in patients with liver cirrhosis.
abstract: The pharmacokinetics of diacerein following a single oral dose of 50 mg was studied in 12 healthy volunteers, 10 patients with a mild liver cirrhosis (Child Pugh's grade A), and 6 patients with a more severe liver cirrhosis (Child Pugh's grade B to C). Statistical analysis using a Kruskal-Wallis test showed no significant differences between the three groups for the following parameters: median Cmax was 3.9 mg l-1 for the cirrhotic patients group I (CPI) and 3.2 mg l-1 for the cirrhotic patients group II (CPII) versus 3.2 mg l-1 for the healthy volunteers (HV); median t1/2 was 4.9 h for CPI and 4.3 h for CPII versus 4.3 h for HV; median Cl/F was 2.1 l h-1 for CPI and 2.5 l h-1 for CPII versus 1.6 l h-1 for HV; median Vdss/F was 12.6 l for CPI and 14.0 l for CPII versus 13.21 for HV. The urinary parameters were comparable. It was concluded that, from a pharmacokinetic point of view, no reduction in the initial dosage of diacerein need be proposed in liver cirrhosis.
authors.affiliation: Department of Pharmacotoxicology, Avicenne Hospital, Bobigny, France.
authors.forename: O
authors.initials: O
authors.lastname: Magnard
authors.forename: K
authors.initials: K
authors.lastname: Louchahi
authors.forename: M
authors.initials: M
authors.lastname: Tod
authors.forename: O
authors.initials: O
authors.lastname: Petitjean
authors.forename: P
authors.initials: P
authors.lastname: Molinier
authors.forename: L
authors.initials: L
authors.lastname: Berdah
authors.forename: G
authors.initials: G
authors.lastname: Perret
mesh_terms: D000328:Adult; D000880:Anthraquinones / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D002214:Capsules; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
chemical_list: D000880:Anthraquinones; D002214:Capsules; C025292:diacerein; C020491:rhein